Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
Anorexia Nervosa
About this trial
This is an interventional treatment trial for Anorexia Nervosa
Eligibility Criteria
Inclusion Criteria:
- Must currently meet DSM-5 criteria for AN-R and AN Spectrum Disorders (i.e., Atypical AN) based on the Structured Clinical Interview for the DSM-5 (SCID-5-RV)
- Have a duration of illness ≥ 6 months
- Be medically stable as assessed by a comprehensive medical and behavioral evaluation conducted by a study physician
Exclusion Criteria:
- Psychotic illness/other mental illness requiring inpatient hospitalization
- Current dependence on drugs or alcohol
- Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight or liver disease which may affect pharmacokinetics of the study drug
- Use of other psychoactive medications
- Significant changes in medication in past month
- Expression of acute suicidality
- Previous hypersensitivity reaction to Epidiolex or any of its constituents
Sites / Locations
- University of California San DiegoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Cannabidiol (CBD)
Placebo
Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses. Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose.
Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.